The authors also found that although IGF-II, IGF binding proteins (IGFBPs) and pregnancy-associated plasma protein-A (PAPP-A) were increased in patients with ovarian cancers, they were not linked with objective clinical response. This evidence concerns the gene PAPPA and ovarian cancer.